在转移性乳腺癌患者的下一代测序 (NGS) 基于分析的现实数据和临床影响

Fabio Canino1,2, Antonio Tornincasa3, Stefania Bettelli4

  • 1Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, 41124 Modena, Italy.

概括

下一代测序 (NGS) 在75%的转移性乳腺癌患者中发现了可操作的突变,导致9%的向治疗变化. 这突出了NGS.